<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01278199</url>
  </required_header>
  <id_info>
    <org_study_id>K081202</org_study_id>
    <nct_id>NCT01278199</nct_id>
  </id_info>
  <brief_title>Bronchial Artery Embolization and Medical Measures in Non Severe Acute Hemoptysis of Mild-moderate Abundance</brief_title>
  <acronym>ARTEMHYS</acronym>
  <official_title>A Multicentric Randomized Trial Comparing the Bronchial Artery Embolization Combined With Medical Measures and the Medical Measures Alone in the Treatment of Non-severe Acute Hemoptysis of Mild-to-moderate Abundance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Severe hemoptysis is a life-threatening condition, with an unpredictable course. The efficacy
      of bronchial artery embolization (BAE) is well established for the treatment of severe
      hemoptysis, with short and long-term bleeding controls obtained in 70 to 100% and 50 to 90%
      of cases, respectively. As complications related to vascular interventional radiology may
      occur in 5 to 10% of cases, the benefit-risk balance might be less clear in acute hemoptysis
      of mild-to-moderate abundance (volume between 100 and 200 ml) and no criteria of severity
      (respiratory failure or hemodynamic instability). There is no available data comparing the
      safety and efficacy of BAE combined with medical measures to those of medical measures alone
      in the treatment of non-severe acute hemoptysis of mild-to-moderate abundance.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a multicentric (n=8) randomized study, involving two parallel groups of patients
      with non-severe acute hemoptysis of mild-to-moderate abundance, related to a systemic
      bronchial or non-bronchial hypervascularization, and comparing the bronchial artery
      embolization combined with medical measures and the medical measures alone in this field.

      The primary aim of the study is to evaluate the efficacy of BAE combined with medical
      measures in the treatment of non-severe acute hemoptysis of mild-to-moderate abundance, as
      compared with that of medical measures alone, by assessing the percentage of recurrence of
      hemoptysis at one month. Bleeding recurrence is defined as a volume of blood expectorated of
      at least 50 ml.

      The second objectives of the study are to compare the efficacy of the two strategies at 3
      months and to assess the safety of both strategies during hospitalization and follow-up.

      Based on a previous study of our group (Reference 8), the number of patients in each group is
      105, assuming a one-month bleeding recurrence rate of 11% in the group receiving BAE, as
      compared with 26% in the group assisted medically (a=.05; β=0.8).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2011</start_date>
  <completion_date type="Actual">February 27, 2017</completion_date>
  <primary_completion_date type="Actual">December 27, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bleeding recurrence rate, after initial therapeutic strategy.</measure>
    <time_frame>One month</time_frame>
    <description>Bleeding recurrence is defined as a volume of expectorated blood of 50 ml or more.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the rate of serious adverse events</measure>
    <time_frame>3 months</time_frame>
    <description>Evaluation of the rate of serious adverse events, according to the therapeutic strategy during hospitalization and follow-up period</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">73</enrollment>
  <condition>Hemoptysis</condition>
  <condition>Acute Disease</condition>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Medicals measures in the treatment of non-severe acute hemoptysis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>bronchial artery embolization (BAE)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Medicals measures</intervention_name>
    <description>Rest in bed. Monitoring of respiratory frequency. Fixation of intravenous route. Administration of nasal oxygenotherapy in order to maintain SpO2 &gt; 90%. Administration of antituberculosis treatment, in case with active pulmonary tuberculosis known at admission or diagnosed during the stay.
If necessary a bronchial wash out of will be realized by a bronchial fibroscopy with measures of use of cold serum, adrenalin xylocain or terlipressin.
The administration of antibiotherapy by general mode according to the clinician appreciation.
The administration of terlipressin according to the clinician appreciation. Against the cough treatment administration according to the clinician appreciation.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>bronchial artery embolization</intervention_name>
    <description>The bronchial artery embolization is practised within 48 hours which follow the hospital admission for non-severe acute hemoptysis.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Non-severe acute hemoptysis (mild-to-moderate abundance and no criteria of severity).

          -  Age &gt; 18 years

          -  Patients with social insurance

        Exclusion Criteria:

          -  Pregnant and/or lactating women

          -  Traumatic hemoptysis

          -  Severe hemoptysis (volume &gt; 200 ml; respiratory failure; hemodynamic instability)

          -  Patients already enrolled in the study within the preceding 3 months

          -  Patients in palliative care, for whom there is no therapeutic plan at short-term

          -  Moribund patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Muriel FARTOUKH, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tenon Hospital, AP-HP</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tenon Hospital, AP-HP</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Mal H, Rullon I, Mellot F, Brugière O, Sleiman C, Menu Y, Fournier M. Immediate and long-term results of bronchial artery embolization for life-threatening hemoptysis. Chest. 1999 Apr;115(4):996-1001.</citation>
    <PMID>10208199</PMID>
  </reference>
  <reference>
    <citation>PURSEL SE, LINDSKOG GE. Hemoptysis. A clinical evaluation of 105 patients examined consecutively on a thoracic surgical service. Am Rev Respir Dis. 1961 Sep;84:329-36.</citation>
    <PMID>13738524</PMID>
  </reference>
  <reference>
    <citation>Hirshberg B, Biran I, Glazer M, Kramer MR. Hemoptysis: etiology, evaluation, and outcome in a tertiary referral hospital. Chest. 1997 Aug;112(2):440-4.</citation>
    <PMID>9266882</PMID>
  </reference>
  <reference>
    <citation>Revel MP, Fournier LS, Hennebicque AS, Cuenod CA, Meyer G, Reynaud P, Frija G. Can CT replace bronchoscopy in the detection of the site and cause of bleeding in patients with large or massive hemoptysis? AJR Am J Roentgenol. 2002 Nov;179(5):1217-24.</citation>
    <PMID>12388502</PMID>
  </reference>
  <reference>
    <citation>Mal H. [Role of surgery in the management of severe haemoptysis]. Rev Mal Respir. 2005 Nov;22(5 Pt 1):717-9. French.</citation>
    <PMID>16272972</PMID>
  </reference>
  <reference>
    <citation>Picard C, Parrot A, Boussaud V, Lavolé A, Saidi F, Mayaud C, Carette MF. Massive hemoptysis due to Rasmussen aneurysm: detection with helicoidal CT angiography and successful steel coil embolization. Intensive Care Med. 2003 Oct;29(10):1837-9. Epub 2003 Sep 13.</citation>
    <PMID>13680121</PMID>
  </reference>
  <reference>
    <citation>Remy J, Lemaitre L, Lafitte JJ, Vilain MO, Saint Michel J, Steenhouwer F. Massive hemoptysis of pulmonary arterial origin: diagnosis and treatment. AJR Am J Roentgenol. 1984 Nov;143(5):963-9.</citation>
    <PMID>6333165</PMID>
  </reference>
  <reference>
    <citation>Fartoukh M, Khalil A, Louis L, Carette MF, Bazelly B, Cadranel J, Mayaud C, Parrot A. An integrated approach to diagnosis and management of severe haemoptysis in patients admitted to the intensive care unit: a case series from a referral centre. Respir Res. 2007 Feb 15;8:11.</citation>
    <PMID>17302979</PMID>
  </reference>
  <reference>
    <citation>Savale L, Parrot A, Khalil A, Antoine M, Théodore J, Carette MF, Mayaud C, Fartoukh M. Cryptogenic hemoptysis: from a benign to a life-threatening pathologic vascular condition. Am J Respir Crit Care Med. 2007 Jun 1;175(11):1181-5. Epub 2007 Mar 1.</citation>
    <PMID>17332480</PMID>
  </reference>
  <reference>
    <citation>Bruzzi JF, Rémy-Jardin M, Delhaye D, Teisseire A, Khalil C, Rémy J. Multi-detector row CT of hemoptysis. Radiographics. 2006 Jan-Feb;26(1):3-22. Review.</citation>
    <PMID>16418239</PMID>
  </reference>
  <reference>
    <citation>Khalil A, Parrot A, Nedelcu C, Fartoukh M, Marsault C, Carette MF. Severe hemoptysis of pulmonary arterial origin: signs and role of multidetector row CT angiography. Chest. 2008 Jan;133(1):212-9. Epub 2007 Nov 7.</citation>
    <PMID>17989162</PMID>
  </reference>
  <reference>
    <citation>Dweik RA, Stoller JK. Role of bronchoscopy in massive hemoptysis. Clin Chest Med. 1999 Mar;20(1):89-105. Review.</citation>
    <PMID>10205720</PMID>
  </reference>
  <reference>
    <citation>Crocco JA, Rooney JJ, Fankushen DS, DiBenedetto RJ, Lyons HA. Massive hemoptysis. Arch Intern Med. 1968 Jun;121(6):495-8.</citation>
    <PMID>5652400</PMID>
  </reference>
  <reference>
    <citation>Garzon AA, Cerruti MM, Golding ME. Exsanguinating hemoptysis. J Thorac Cardiovasc Surg. 1982 Dec;84(6):829-33.</citation>
    <PMID>7144217</PMID>
  </reference>
  <reference>
    <citation>Jewkes J, Kay PH, Paneth M, Citron KM. Pulmonary aspergilloma: analysis of prognosis in relation to haemoptysis and survey of treatment. Thorax. 1983 Aug;38(8):572-8.</citation>
    <PMID>6612647</PMID>
  </reference>
  <reference>
    <citation>Knott-Craig CJ, Oostuizen JG, Rossouw G, Joubert JR, Barnard PM. Management and prognosis of massive hemoptysis. Recent experience with 120 patients. J Thorac Cardiovasc Surg. 1993 Mar;105(3):394-7.</citation>
    <PMID>8445918</PMID>
  </reference>
  <reference>
    <citation>Håkanson E, Konstantinov IE, Fransson SG, Svedjeholm R. Management of life-threatening haemoptysis. Br J Anaesth. 2002 Feb;88(2):291-5.</citation>
    <PMID>11878664</PMID>
  </reference>
  <reference>
    <citation>Jean-Baptiste E. Clinical assessment and management of massive hemoptysis. Crit Care Med. 2000 May;28(5):1642-7. Review.</citation>
    <PMID>10834728</PMID>
  </reference>
  <reference>
    <citation>Lordan JL, Gascoigne A, Corris PA. The pulmonary physician in critical care * Illustrative case 7: Assessment and management of massive haemoptysis. Thorax. 2003 Sep;58(9):814-9. Review.</citation>
    <PMID>12947147</PMID>
  </reference>
  <reference>
    <citation>Haponik EF, Chin R. Hemoptysis: clinicians' perspectives. Chest. 1990 Feb;97(2):469-75.</citation>
    <PMID>2298074</PMID>
  </reference>
  <reference>
    <citation>Haponik EF, Fein A, Chin R. Managing life-threatening hemoptysis: has anything really changed? Chest. 2000 Nov;118(5):1431-5.</citation>
    <PMID>11083697</PMID>
  </reference>
  <reference>
    <citation>Rémy J, Arnaud A, Fardou H, Giraud R, Voisin C. Treatment of hemoptysis by embolization of bronchial arteries. Radiology. 1977 Jan;122(1):33-7.</citation>
    <PMID>830351</PMID>
  </reference>
  <reference>
    <citation>Ramon P, Wallaert B, Derollez M, D'Odemont JP, Tonnel AB. [Treatment of severe hemoptysis with terlipressin. Study of the efficacy and tolerance of this product]. Rev Mal Respir. 1989;6(4):365-8. French.</citation>
    <PMID>2799045</PMID>
  </reference>
  <reference>
    <citation>White RI Jr. Bronchial artery embolotherapy for control of acute hemoptysis: analysis of outcome. Chest. 1999 Apr;115(4):912-5.</citation>
    <PMID>10208183</PMID>
  </reference>
  <reference>
    <citation>Rémy J, Voisin C, Dupuis C, Beguery P, Tonnel AB, Denies JL, Douay B. [Treatment of hemoptysis by embolization of the systemic circulation]. Ann Radiol (Paris). 1974 Jan-Feb;17(1):5-16. French.</citation>
    <PMID>4820232</PMID>
  </reference>
  <reference>
    <citation>Cremaschi P, Nascimbene C, Vitulo P, Catanese C, Rota L, Barazzoni GC, Cornalba GP. Therapeutic embolization of bronchial artery: a successful treatment in 209 cases of relapse hemoptysis. Angiology. 1993 Apr;44(4):295-9.</citation>
    <PMID>8457080</PMID>
  </reference>
  <reference>
    <citation>Uflacker R, Kaemmerer A, Picon PD, Rizzon CF, Neves CM, Oliveira ES, Oliveira ME, Azevedo SN, Ossanai R. Bronchial artery embolization in the management of hemoptysis: technical aspects and long-term results. Radiology. 1985 Dec;157(3):637-44.</citation>
    <PMID>4059552</PMID>
  </reference>
  <reference>
    <citation>Mesurolle B, Lacombe P, Barre O, Qanadli S, Mulot RO, Chagnon S. [Failures and complications of bronchial artery embolization]. Rev Mal Respir. 1996 Jul;13(3):217-25. Review. French.</citation>
    <PMID>8765913</PMID>
  </reference>
  <reference>
    <citation>Ramakantan R, Bandekar VG, Gandhi MS, Aulakh BG, Deshmukh HL. Massive hemoptysis due to pulmonary tuberculosis: control with bronchial artery embolization. Radiology. 1996 Sep;200(3):691-4.</citation>
    <PMID>8756916</PMID>
  </reference>
  <reference>
    <citation>Rabkin JE, Astafjev VI, Gothman LN, Grigorjev YG. Transcatheter embolization in the management of pulmonary hemorrhage. Radiology. 1987 May;163(2):361-5.</citation>
    <PMID>3562815</PMID>
  </reference>
  <reference>
    <citation>Hayakawa K, Tanaka F, Torizuka T, Mitsumori M, Okuno Y, Matsui A, Satoh Y, Fujiwara K, Misaki T. Bronchial artery embolization for hemoptysis: immediate and long-term results. Cardiovasc Intervent Radiol. 1992 May-Jun;15(3):154-8; discussion 158-9.</citation>
    <PMID>1628281</PMID>
  </reference>
  <reference>
    <citation>Swanson KL, Johnson CM, Prakash UB, McKusick MA, Andrews JC, Stanson AW. Bronchial artery embolization : experience with 54 patients. Chest. 2002 Mar;121(3):789-95.</citation>
    <PMID>11888961</PMID>
  </reference>
  <reference>
    <citation>Wong ML, Szkup P, Hopley MJ. Percutaneous embolotherapy for life-threatening hemoptysis. Chest. 2002 Jan;121(1):95-102.</citation>
    <PMID>11796437</PMID>
  </reference>
  <reference>
    <citation>Ong TH, Eng P. Massive hemoptysis requiring intensive care. Intensive Care Med. 2003 Feb;29(2):317-20. Epub 2002 Nov 2.</citation>
    <PMID>12594593</PMID>
  </reference>
  <reference>
    <citation>Labbe V, Roques S, Boughdène F, Razazi K, Khalil A, Parrot A, Fartoukh M. Shock complicating successful bronchial artery embolization for severe hemoptysis. Chest. 2009 Jan;135(1):215-217. doi: 10.1378/chest.08-0491.</citation>
    <PMID>19136409</PMID>
  </reference>
  <reference>
    <citation>Lacerda JE, Consolim-Colombo FM, Moreira ED, Ida F, Silva GJ, Irigoyen MC, Krieger EM. Influence of cardiopulmonary reflex on the sympathetic activity during myocardial infarction. Auton Neurosci. 2007 May 30;133(2):128-35. Epub 2006 Dec 26.</citation>
    <PMID>17188942</PMID>
  </reference>
  <reference>
    <citation>Remy-Jardin M, Bouaziz N, Dumont P, Brillet PY, Bruzzi J, Remy J. Bronchial and nonbronchial systemic arteries at multi-detector row CT angiography: comparison with conventional angiography. Radiology. 2004 Dec;233(3):741-9. Epub 2004 Oct 14.</citation>
    <PMID>15486218</PMID>
  </reference>
  <reference>
    <citation>Yoon YC, Lee KS, Jeong YJ, Shin SW, Chung MJ, Kwon OJ. Hemoptysis: bronchial and nonbronchial systemic arteries at 16-detector row CT. Radiology. 2005 Jan;234(1):292-8. Epub 2004 Nov 18.</citation>
    <PMID>15550375</PMID>
  </reference>
  <reference>
    <citation>Straus DJ, Yahalom J, Gaynor J, Myers J, Koziner B, Caravelli J, Lee BJ 3rd, Nisce LZ, McCormick B, Bajorunas D, et al. Four cycles of chemotherapy and regional radiation therapy for clinical early-stage and intermediate-stage Hodgkin's disease. Cancer. 1992 Feb 15;69(4):1052-60.</citation>
    <PMID>1370915</PMID>
  </reference>
  <reference>
    <citation>JACKSON GG, ARANA-SIALER JA, ANDERSEN BR GRIEBLE HG, McCABE WR. Profiles of pyelonephritis. Arch Intern Med. 1962 Nov;110:63-75.</citation>
    <PMID>13957202</PMID>
  </reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 14, 2011</study_first_submitted>
  <study_first_submitted_qc>January 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 17, 2011</study_first_posted>
  <last_update_submitted>March 21, 2017</last_update_submitted>
  <last_update_submitted_qc>March 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bronchial Artery Embolization</keyword>
  <keyword>Non-severe Hemoptysis</keyword>
  <keyword>Bleeding mild-to-moderate abundance</keyword>
  <keyword>Volume ranging from 100 ml to 200 ml</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemoptysis</mesh_term>
    <mesh_term>Acute Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

